Every year, DZL allocates part of its budget to innovative clinical trials that are based on initiatives by DZL scientists (Investigator Initiated Trials). Four more trials, which will be described more specifically hereinafter, will be...
A team of DZL researchers has developed a novel tool to measure the activity of two proteins implicated in lung inflammation in cystic fibrosis.
EMA, the European Medicines Agency, approved Kaftrio, a new triple-combination therapy for the treatment of cystic fibrosis.
Although research is advancing with great strides, the life expectancy of people with cystic fibrosis (CF) is still significantly reduced.
The DZL was represented with an information desk at the 60th Congress of the German Respiratory Society (DGP), which took place in Munich from March 13–16, 2019.
Chronic infections with the pathogen Pseudomonas aeruginosa change the lung microbiome in CF-patients.
Cystic Fibrosis: Junior Scientist Dr. Patricia Morán Losada...
Results recently published confirm the sensitivity of magnetic resonance imaging (MRI) and the lung clearance index (LCI), a measure of abnormal ventilation distribution...
TLRC Researcher receives Christiane Herzog Research Award 2014.
DZL Director Marcus Mall and DZL Scientific Advisory Board member Stuart Elborn co-edited the European Respiratory Monograph on Cystic Fibrosis (CF)
DZLresearchers from the TLRC site publish breakthrough method for non-invasive early diagnosis of pulmonary changes in infants and young children with cystic fibrosis
DZL Faculty Member, Dr. Frauke Stanke is awarded the 2013 Adolf-Windorfer Prize for groundbreaking work in the field of Cystic Fibrosis.
